[Expressing foreign genes by Newcastle disease virus for cancer therapy]
/in International Publications, Newcastle Disease Virus /von 2015-03-01 / Mol. Biol. (Mosk.) 2015 Mar-Apr;49(2):195-204Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2015-03-01 / Anticancer Res. 2015 Mar;35(3):1575-82Concomitant trimodality therapy of re-irradiation, chemotherapy and regional hyperthermia for a pretreated inoperable sarcoma recurrence
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2015-03-01 / Tumori 2015 Mar-Apr;101(2):e54-6Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-42PET response criteria in solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2015-02-26 / J. Nucl. Med. 2015 Apr;56(4):530-7Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling
/in Glioblastoma, Hyperthermia, International Publications /von 2015-02-20 / Cancer Res. 2015 Apr;75(8):1760-9Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2015-02-16 / Int. Immunopharmacol. 2015 Apr;25(2):450-6Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
/in Hyperthermia, International Publications /von 2015-02-12 / Cell Death Dis 2015 Feb;6:e1633Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2015-02-11 / Cancer Res. 2015 Apr;75(7):1265-74
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de